Stockreport

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable GrowthExpected Phase 3 Data Readouts in 2025 for Oveporexton (TAK-861), [Read more]